EP2195341B1
(en)
|
2007-09-26 |
2017-03-22 |
UCB Biopharma SPRL |
Dual specificity antibody fusions
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
PT2334705T
(pt)
|
2008-09-26 |
2017-03-22 |
Ucb Biopharma Sprl |
Produtos biológicos
|
KR20190064664A
(ko)
|
2008-10-02 |
2019-06-10 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
Cd86 길항제 다중-표적 결합 단백질
|
AU2010230563A1
(en)
|
2009-04-02 |
2011-09-22 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain Fab fragments
|
US20100256340A1
(en)
|
2009-04-07 |
2010-10-07 |
Ulrich Brinkmann |
Trivalent, bispecific antibodies
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
US8703132B2
(en)
|
2009-06-18 |
2014-04-22 |
Hoffmann-La Roche, Inc. |
Bispecific, tetravalent antigen binding proteins
|
JO3182B1
(ar)
*
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
NZ701769A
(en)
|
2009-09-16 |
2016-06-24 |
Genentech Inc |
Coiled coil and/or tether containing protein complexes and uses thereof
|
CN105693861A
(zh)
*
|
2009-12-29 |
2016-06-22 |
新兴产品开发西雅图有限公司 |
异二聚体结合蛋白及其应用
|
GB201000467D0
(en)
*
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
SG187119A1
(en)
|
2010-07-19 |
2013-02-28 |
Hoffmann La Roche |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
KR20130126576A
(ko)
|
2010-07-19 |
2013-11-20 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
RU2013106217A
(ru)
|
2010-08-05 |
2014-09-10 |
Ф. Хоффманн-Ля Рош Аг |
Гибридный белок из антитела против мнс и противовирусного цитокина
|
CN103068846B9
(zh)
|
2010-08-24 |
2016-09-28 |
弗·哈夫曼-拉罗切有限公司 |
包含二硫键稳定性Fv片段的双特异性抗体
|
AU2011325833C1
(en)
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
CN103429737B
(zh)
|
2010-11-30 |
2020-07-14 |
中外制药株式会社 |
细胞毒诱导治疗剂
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
TW201309330A
(zh)
*
|
2011-01-28 |
2013-03-01 |
Abbott Lab |
包含糖基化抗體之組合物及其用途
|
CA2824824A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
CA2825081A1
(en)
|
2011-02-28 |
2012-09-07 |
Birgit Bossenmaier |
Antigen binding proteins
|
MX346486B
(es)
|
2011-04-19 |
2017-03-22 |
Merrimack Pharmaceuticals Inc |
Anticuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos.
|
BR112013026423A2
(pt)
|
2011-04-20 |
2016-11-29 |
Roche Glycart Ag |
método e construtos para a passagem de pendente do ph da barreira sangue-cérebro
|
BR112013032235A2
(pt)
|
2011-06-15 |
2016-11-22 |
Hoffmann La Roche |
anticorpos do receptor de epo anti-humano e métodos de uso
|
MX354663B
(es)
|
2011-06-22 |
2018-03-14 |
Hoffmann La Roche |
Eliminación de células diana por parte de células t citotóxicas específicas de virus utilizando complejos que comprenden mhc de clase i.
|
LT2748202T
(lt)
*
|
2011-08-23 |
2018-09-25 |
Roche Glycart Ag |
Bispecifinės antigeną surišančios molekulės
|
US20130078250A1
(en)
*
|
2011-08-23 |
2013-03-28 |
Oliver Ast |
Bispecific t cell activating antigen binding molecules
|
WO2013026839A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
UA116192C2
(uk)
*
|
2011-08-23 |
2018-02-26 |
Рош Глікарт Аг |
Активуюча т-клітини біоспецифічна антигензв'язуюча молекула
|
KR101723273B1
(ko)
*
|
2011-08-23 |
2017-04-04 |
로슈 글리카트 아게 |
2 개의 fab 단편을 포함하는 fc-부재 항체 및 이용 방법
|
JP2014530009A
(ja)
|
2011-09-29 |
2014-11-17 |
エーピーオー‐ティー ビー.ヴイ. |
異常細胞を標的とする多重特異性結合分子
|
KR102052774B1
(ko)
|
2011-11-04 |
2019-12-04 |
자임워크스 인코포레이티드 |
Fc 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
|
CA2853917A1
(en)
|
2011-12-19 |
2013-06-27 |
F. Hoffmann-La Roche Ag |
Method for the detection of free binding partner of a multispecific binder
|
WO2013092743A2
(en)
|
2011-12-22 |
2013-06-27 |
F. Hoffmann-La Roche Ag |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
CA2853955C
(en)
|
2011-12-22 |
2021-09-28 |
F. Hoffmann-La Roche Ag |
Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
|
BR112014013035A2
(pt)
|
2011-12-22 |
2018-10-09 |
Hoffmann La Roche |
métodos de seleção de células, conjuntos de expressão bicistrônica, células eucarióticas, vetores lentivirais, uso de vetor lentiviral, bibliotecas de ventores lentivirais e de células eucarióticas, métodos de seleção de células, fluxos de trabalho e uso de célula
|
JP2015504895A
(ja)
|
2012-01-13 |
2015-02-16 |
エーピーオー‐ティー ビー.ヴイ. |
毒性部分を備える異常細胞拘束性免疫グロブリン
|
CN104105966B
(zh)
|
2012-02-01 |
2016-10-26 |
弗·哈夫曼-拉罗切有限公司 |
用于检测多特异性结合物的结合搭档的方法
|
US10633451B2
(en)
|
2012-02-03 |
2020-04-28 |
Hoffmann-La Roche Inc. |
Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
|
MX2014009565A
(es)
|
2012-02-10 |
2014-11-10 |
Genentech Inc |
Anticuerpos monocatenarios y otros heteromultimeros.
|
WO2013120929A1
(en)
|
2012-02-15 |
2013-08-22 |
F. Hoffmann-La Roche Ag |
Fc-receptor based affinity chromatography
|
US20150110788A1
(en)
*
|
2012-03-06 |
2015-04-23 |
Galaxy Biotech, Llc |
Bispecific antibodies with an fgf2 binding domain
|
SG10201608307WA
(en)
|
2012-04-20 |
2016-11-29 |
Emergent Product Dev Seattle |
Cd3 binding polypeptides
|
RU2014149681A
(ru)
*
|
2012-05-24 |
2016-07-20 |
Ф. Хоффманн-Ля Рош Аг |
Антитела с множественной специфичностью
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
RU2015100656A
(ru)
|
2012-06-27 |
2016-08-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
|
KR20150023889A
(ko)
|
2012-06-27 |
2015-03-05 |
에프. 호프만-라 로슈 아게 |
2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도
|
SG11201407420RA
(en)
|
2012-07-04 |
2015-02-27 |
Hoffmann La Roche |
Covalently linked antigen-antibody conjugates
|
RU2630664C2
(ru)
|
2012-07-04 |
2017-09-11 |
Ф. Хоффманн-Ля Рош Аг |
Антитела к теофиллину и способы их применения
|
RU2630296C2
(ru)
|
2012-07-04 |
2017-09-06 |
Ф. Хоффманн-Ля Рош Аг |
Антитела к биотину и способы их применения
|
CN104471397B
(zh)
|
2012-07-13 |
2018-03-23 |
弗·哈夫曼-拉罗切有限公司 |
用于检测多特异性结合物的方法
|
IN2015DN01299A
(pt)
*
|
2012-07-23 |
2015-07-03 |
Zymeworks Inc |
|
CN104619715B
(zh)
|
2012-09-14 |
2018-06-05 |
弗·哈夫曼-拉罗切有限公司 |
包含至少两个不同实体的分子的生产和选择方法及其用途
|
JP6273205B2
(ja)
|
2012-10-05 |
2018-01-31 |
協和発酵キリン株式会社 |
ヘテロダイマータンパク質組成物
|
EP2904016B1
(en)
|
2012-10-08 |
2018-11-14 |
Roche Glycart AG |
Fc-free antibodies comprising two fab-fragments and methods of use
|
AR093378A1
(es)
|
2012-11-08 |
2015-06-03 |
Hoffmann La Roche |
PROTEINAS LIGANTES DE ANTIGENO HER3 DE UNION A LA HORQUILLA b DE HER3
|
KR102168562B1
(ko)
*
|
2012-11-19 |
2020-10-22 |
발리오팜 아게 |
Cd20 및 cd95에 결합하는 재조합 이중특이성 항체
|
KR102545617B1
(ko)
|
2012-11-28 |
2023-06-20 |
자임워크스 비씨 인코포레이티드 |
가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
GB201223276D0
(en)
*
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
CA3211863A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
JP2016512421A
(ja)
*
|
2013-02-26 |
2016-04-28 |
ロシュ グリクアート アーゲー |
二重特異性t細胞活性化抗原結合分子
|
EP2961771B1
(en)
|
2013-02-26 |
2020-01-01 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules specific to cd3 and cea
|
WO2014131694A1
(en)
*
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
EP2970485A1
(en)
*
|
2013-03-15 |
2016-01-20 |
Merck Patent GmbH |
Tetravalent bispecific antibodies
|
US10544187B2
(en)
|
2013-03-15 |
2020-01-28 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
KR102049990B1
(ko)
*
|
2013-03-28 |
2019-12-03 |
삼성전자주식회사 |
c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
AU2014261630B2
(en)
|
2013-04-29 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Human FcRn-binding modified antibodies and methods of use
|
RU2019108429A
(ru)
|
2013-04-29 |
2019-05-06 |
Ф. Хоффманн-Ля Рош Аг |
Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
|
CN105164158A
(zh)
|
2013-04-29 |
2015-12-16 |
豪夫迈·罗氏有限公司 |
消除对FcRn-结合的抗-IGF-1R抗体及其在血管性眼病治疗中的用途
|
WO2015025054A1
(en)
|
2013-08-22 |
2015-02-26 |
Medizinische Universität Wien |
Dye-specific antibodies for prestained molecular weight markers and methods producing the same
|
MX2016003593A
(es)
|
2013-10-11 |
2016-06-02 |
Hoffmann La Roche |
Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
|
CN104558194B
(zh)
*
|
2013-10-17 |
2018-04-27 |
泰州迈博太科药业有限公司 |
一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
|
SI3071597T1
(sl)
|
2013-11-21 |
2020-11-30 |
F. Hoffmann-La Roche Ag |
Anti alfa-sinukleinska protitelesa in postopki uporabe
|
RU2016129517A
(ru)
|
2013-12-20 |
2018-01-25 |
Ф. Хоффманн-Ля Рош Аг |
Биспецифические антитела к her2 и способы применения
|
AU2014368696A1
(en)
|
2013-12-20 |
2016-06-02 |
F. Hoffmann-La Roche Ag |
Humanized anti-Tau(pS422) antibodies and methods of use
|
TW201609805A
(zh)
|
2013-12-23 |
2016-03-16 |
美國禮來大藥廠 |
結合egfr及met之多功能抗體
|
KR20160104628A
(ko)
|
2014-01-03 |
2016-09-05 |
에프. 호프만-라 로슈 아게 |
이중특이성 항-합텐/항-혈액뇌장벽 수용체 항체, 그의 복합체 및 혈액뇌장벽 셔틀로서 그의 용도
|
KR102278429B1
(ko)
|
2014-01-03 |
2021-07-16 |
에프. 호프만-라 로슈 아게 |
공유 연결된 폴리펩티드 독소-항체 콘쥬게이트
|
CN105873615B
(zh)
|
2014-01-03 |
2020-12-25 |
豪夫迈·罗氏有限公司 |
共价连接的helicar-抗helicar抗体缀合物及其用途
|
CA2932547C
(en)
|
2014-01-06 |
2023-05-23 |
F. Hoffmann-La Roche Ag |
Monovalent blood brain barrier shuttle modules
|
KR20160107190A
(ko)
|
2014-01-15 |
2016-09-13 |
에프. 호프만-라 로슈 아게 |
변형된 FcRn-결합 및 유지된 단백질 A-결합 성질을 갖는 Fc-영역 변이체
|
AU2015237184B2
(en)
|
2014-03-28 |
2020-11-26 |
Xencor, Inc. |
Bispecific antibodies that bind to CD38 and CD3
|
CN113092788A
(zh)
|
2014-04-02 |
2021-07-09 |
豪夫迈·罗氏有限公司 |
检测多特异性抗体轻链错配的方法
|
TWI726842B
(zh)
|
2014-04-07 |
2021-05-11 |
日商中外製藥股份有限公司 |
免疫活化抗原結合分子
|
EP2930188A1
(en)
*
|
2014-04-13 |
2015-10-14 |
Affimed Therapeutics AG |
Trifunctional antigen-binding molecule
|
KR102223502B1
(ko)
*
|
2014-05-09 |
2021-03-05 |
삼성전자주식회사 |
항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
|
EP3144388B1
(en)
|
2014-05-13 |
2020-07-01 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirecting antigen-binding molecule for cells having immunosuppression function
|
EP4026850A1
(en)
|
2014-05-28 |
2022-07-13 |
Zymeworks Inc. |
Modified antigen binding polypeptide constructs and uses thereof
|
SG10201913680PA
(en)
*
|
2014-05-29 |
2020-03-30 |
Macrogenics Inc |
Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
EP3164419A1
(en)
|
2014-06-26 |
2017-05-10 |
F. Hoffmann-La Roche AG |
Anti-brdu antibodies and methods of use
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
US9884921B2
(en)
|
2014-07-01 |
2018-02-06 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
CN107074925B
(zh)
|
2014-07-10 |
2021-08-24 |
阿费里斯股份公司 |
用于预防和/或治疗亨廷顿氏病的物质和方法
|
NZ766556A
(en)
|
2014-08-04 |
2024-02-23 |
Hoffmann La Roche |
Bispecific t cell activating antigen binding molecules
|
PE20170894A1
(es)
|
2014-09-26 |
2017-07-12 |
Macrogenics Inc |
Diacuerpos monovalentes biepecificos que son capaces de unir cd19 y cd3 y usos de los mismos
|
EP3215528B1
(en)
|
2014-11-06 |
2019-08-07 |
F.Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn-binding and methods of use
|
CN107074966A
(zh)
|
2014-11-06 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
具有改变的FCRN‑和蛋白A‑结合性质的Fc区变体
|
SI3789402T1
(sl)
|
2014-11-20 |
2022-10-28 |
F. Hoffmann-La Roche Ag |
Kombinirano zdravljenje z bispecifičnimi molekulami, ki vežejo antigen in aktivirajo celice T, ter antagonisti za vezavo osi PD-1
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
TN2017000222A1
(en)
|
2014-11-26 |
2018-10-19 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and cd38
|
CU24597B1
(es)
|
2014-11-26 |
2022-05-11 |
Xencor Inc |
Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20
|
EP3227341A1
(en)
|
2014-12-02 |
2017-10-11 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
|
WO2016087416A1
(en)
*
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
CN107207592B
(zh)
*
|
2014-12-05 |
2021-11-23 |
默克专利有限公司 |
结构域交换的抗体
|
EP3234598B1
(en)
|
2014-12-18 |
2019-11-06 |
F.Hoffmann-La Roche Ag |
Assay and method for determining cdc eliciting antibodies
|
US10428155B2
(en)
*
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
AU2015380455A1
(en)
|
2015-01-26 |
2017-08-03 |
Macrogenics, Inc. |
Multivalent molecules comprising DR5-binding domains
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
EP3313877B1
(en)
|
2015-06-24 |
2020-06-03 |
H. Hoffnabb-La Roche Ag |
Humanized anti-tau(ps422) antibodies and methods of use
|
EA201890177A1
(ru)
*
|
2015-06-30 |
2018-06-29 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Мультиспецифические связывающие белки
|
KR20180093127A
(ko)
|
2015-07-30 |
2018-08-20 |
마크로제닉스, 인크. |
Pd-1-결합 분자 및 그것의 사용 방법
|
JP7002446B2
(ja)
|
2015-09-21 |
2022-03-04 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
Cd3結合ポリペプチド
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
DK3356404T3
(da)
|
2015-10-02 |
2021-10-25 |
Hoffmann La Roche |
Anti-pd1-antistoffer og fremgangsmåder til anvendelse
|
CR20180162A
(es)
|
2015-10-02 |
2018-05-25 |
Hoffmann La Roche |
Moléculas biespecíficas de unión a antígeno activadoras de células t
|
WO2017055399A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Cellular based fret assay for the determination of simultaneous binding
|
IL258521B2
(en)
|
2015-10-08 |
2024-01-01 |
Macrogenics Inc |
Combination of treatments for cancer treatment
|
RU2018116846A
(ru)
|
2015-10-08 |
2019-11-08 |
Займворкс Инк. |
Антигенсвязывающие полипептидные конструкции, содержащие легкие цепи каппа и лямбда, и их применения
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
WO2017072210A1
(en)
|
2015-10-29 |
2017-05-04 |
F. Hoffmann-La Roche Ag |
Anti-variant fc-region antibodies and methods of use
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
CA3007030A1
(en)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
AU2016368469B2
(en)
|
2015-12-09 |
2023-11-02 |
F. Hoffmann-La Roche Ag |
Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
|
US10954301B2
(en)
|
2015-12-14 |
2021-03-23 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
WO2017117464A1
(en)
|
2015-12-30 |
2017-07-06 |
Kodiak Sciences Inc. |
Antibodies and conjugates thereof
|
EP3862365A1
(en)
|
2016-01-08 |
2021-08-11 |
F. Hoffmann-La Roche AG |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
TW201730212A
(zh)
|
2016-02-17 |
2017-09-01 |
宏觀基因股份有限公司 |
Ror1-結合分子及其使用方法
|
JP7015244B2
(ja)
|
2016-03-22 |
2022-02-02 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化t細胞二重特異性分子
|
EP3432927A4
(en)
*
|
2016-03-24 |
2019-11-20 |
Gensun Biopharma Inc. |
TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
|
CA3020864A1
(en)
|
2016-04-15 |
2017-10-19 |
Macrogenics, Inc. |
Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
|
WO2017218707A2
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
CN109563124A
(zh)
|
2016-06-17 |
2019-04-02 |
豪夫迈·罗氏有限公司 |
多特异性抗体的纯化
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
EP3484516A4
(en)
|
2016-07-14 |
2020-03-18 |
Fred Hutchinson Cancer Research Center |
MULTIPLE CONSTRUCTIONS OF BI-SPECIFIC LINK AREAS HAVING A DIFFERENT EPITOPE LINK TO TREAT CANCER
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2018050878A1
(en)
|
2016-09-19 |
2018-03-22 |
F. Hoffmann-La Roche Ag |
Complement factor based affinity chromatography
|
EP3519820B1
(en)
|
2016-09-30 |
2020-12-09 |
H. Hoffnabb-La Roche Ag |
Spr-based dual-binding assay for the functional analysis of multispecific molecules
|
EP3519436A4
(en)
|
2016-09-30 |
2020-09-09 |
Baylor College of Medicine |
TISSUE-ORIENTED ANTIBODY-BASED GENE THERAPY
|
CN109843926B
(zh)
|
2016-09-30 |
2023-01-20 |
豪夫迈·罗氏有限公司 |
针对cd3的双特异性抗体
|
JP7142630B2
(ja)
|
2016-10-14 |
2022-09-27 |
ゼンコア インコーポレイテッド |
IL15/IL15Rαヘテロ二量体FC-融合タンパク質
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
MA46893A
(fr)
|
2016-11-23 |
2019-10-02 |
Bioverativ Therapeutics Inc |
Anticorps bispécifiques se liant au facteur ix de coagulation et au facteur x de coagulation
|
AU2017381656B2
(en)
|
2016-12-21 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
Re-use of enzymes in in vitro glycoengineering of antibodies
|
EP3559249A1
(en)
|
2016-12-21 |
2019-10-30 |
H. Hoffnabb-La Roche Ag |
Method for in vitro glycoengineering of antibodies
|
BR112019010485A2
(pt)
|
2016-12-21 |
2019-09-10 |
Hoffmann La Roche |
método para a produção de um anticorpo, anticorpo e formulação farmacêutica
|
AU2017382234A1
(en)
|
2016-12-23 |
2019-07-04 |
Macrogenics, Inc. |
ADAM9-binding molecules, and methods of use thereof
|
MX2019007984A
(es)
|
2017-02-02 |
2019-10-15 |
Merck Patent Gmbh |
Apareamiento preferido de dominios de anticuerpos.
|
MX2019009967A
(es)
|
2017-02-24 |
2019-12-02 |
Macrogenics Inc |
Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas.
|
JP7247101B2
(ja)
|
2017-04-03 |
2023-03-28 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Steap-1に結合する抗体
|
KR102408873B1
(ko)
|
2017-04-05 |
2022-06-15 |
에프. 호프만-라 로슈 아게 |
Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
|
PL3606954T3
(pl)
|
2017-04-05 |
2022-10-17 |
F. Hoffmann-La Roche Ag |
Przeciwciała anty-LAG3
|
CA3068049A1
(en)
*
|
2017-06-25 |
2019-01-03 |
Systimmune, Inc. |
Multi-specific antibodies and methods of making and using thereof
|
US11787863B2
(en)
*
|
2017-06-25 |
2023-10-17 |
Systimmune, Inc. |
Multi-specific antibodies and methods of making and using thereof
|
CA3064966A1
(en)
|
2017-06-30 |
2019-01-03 |
Zymeworks Inc. |
Stabilized chimeric fabs
|
US11084863B2
(en)
|
2017-06-30 |
2021-08-10 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
|
EP3625250B1
(en)
*
|
2017-07-21 |
2021-04-14 |
Trianni, Inc. |
Single chain vh and heavy chain antibodies
|
US11161911B2
(en)
|
2017-10-23 |
2021-11-02 |
Go Therapeutics, Inc. |
Anti-glyco-MUC1 antibodies and their uses
|
US11312770B2
(en)
|
2017-11-08 |
2022-04-26 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2019105916A1
(en)
|
2017-11-29 |
2019-06-06 |
F. Hoffmann-La Roche Ag |
Target interference suppressed anti-drug antibody assay
|
RU2020122822A
(ru)
|
2017-12-12 |
2022-01-13 |
Макродженикс, Инк. |
Биспецифичные связывающие cd16 молекулы и их применение при лечении заболеваний
|
WO2019125732A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
CN111527107A
(zh)
|
2017-12-21 |
2020-08-11 |
豪夫迈·罗氏有限公司 |
结合hla-a2/wt1的抗体
|
CN111491951A
(zh)
|
2017-12-22 |
2020-08-04 |
豪夫迈·罗氏有限公司 |
通过疏水相互作用色谱法耗尽轻链错配的抗体变体
|
EP3731864A1
(en)
|
2017-12-29 |
2020-11-04 |
F. Hoffmann-La Roche SA |
Anti-vegf antibodies and methods of use
|
EP3746480A1
(en)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
CN111630063A
(zh)
|
2018-01-31 |
2020-09-04 |
豪夫迈·罗氏有限公司 |
稳定化的免疫球蛋白结构域
|
MA51793A
(fr)
|
2018-02-08 |
2020-12-16 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
JP7337079B2
(ja)
|
2018-02-15 |
2023-09-01 |
マクロジェニクス,インコーポレーテッド |
変異型cd3結合ドメイン、及び疾患の治療のための併用療法におけるその使用
|
CN111936625A
(zh)
|
2018-03-29 |
2020-11-13 |
豪夫迈·罗氏有限公司 |
调节哺乳动物细胞中的生乳活性
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
JP2021521784A
(ja)
|
2018-04-18 |
2021-08-30 |
ゼンコア インコーポレイテッド |
IL−15/IL−15RaFc融合タンパク質とPD−1抗原結合ドメインを含むPD−1標的化ヘテロダイマー融合タンパク質およびそれらの使用
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
WO2019224718A2
(en)
|
2018-05-24 |
2019-11-28 |
Janssen Biotech, Inc. |
Psma binding agents and uses thereof
|
TW202016151A
(zh)
|
2018-06-09 |
2020-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
TWI754157B
(zh)
|
2018-07-25 |
2022-02-01 |
大陸商信達生物製藥(蘇州)有限公司 |
抗tigit抗體及其用途
|
MA50586A
(fr)
|
2018-08-09 |
2020-09-16 |
Regeneron Pharma |
Procédés d'évaluation de l'affinité de liaison d'une variante d'anticorps au récepteur fc néonatal
|
CN113195523A
(zh)
|
2018-10-03 |
2021-07-30 |
Xencor股份有限公司 |
IL-12异源二聚体Fc融合蛋白
|
CN109633053B
(zh)
*
|
2018-12-19 |
2021-04-30 |
杭州奕安济世生物药业有限公司 |
细胞培养物蛋白质表达量和蛋白质聚集体量的检测方法
|
PE20211603A1
(es)
|
2018-12-21 |
2021-08-18 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3
|
EP3902823A1
(en)
|
2018-12-24 |
2021-11-03 |
Sanofi |
Multispecific binding proteins with mutant fab domains
|
EP3902560A1
(en)
|
2018-12-28 |
2021-11-03 |
F. Hoffmann-La Roche AG |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
EP3903102B1
(en)
|
2018-12-30 |
2023-04-12 |
F. Hoffmann-La Roche AG |
Ph-gradient spr-based binding assay
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
WO2020200941A1
(en)
|
2019-03-29 |
2020-10-08 |
F. Hoffmann-La Roche Ag |
Spr-based binding assay for the functional analysis of multivalent molecules
|
WO2020200944A1
(en)
|
2019-03-29 |
2020-10-08 |
F. Hoffmann-La Roche Ag |
Method for generating avid-binding multispecific antibodies
|
AR118720A1
(es)
|
2019-04-19 |
2021-10-27 |
Janssen Biotech Inc |
Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
|
WO2020229378A1
(en)
|
2019-05-13 |
2020-11-19 |
F. Hoffmann-La Roche Ag |
Interference-suppressed pharmacokinetic immunoassay
|
CN114258403A
(zh)
|
2019-06-19 |
2022-03-29 |
豪夫迈·罗氏有限公司 |
通过以限定的组织形式靶向整合多个表达盒来产生多价多特异性抗体表达细胞的方法
|
KR20220024637A
(ko)
|
2019-06-19 |
2022-03-03 |
에프. 호프만-라 로슈 아게 |
정의된 조직의 다수 발현 카세트들의 표적화 통합에 의한 3가 항체 발현 세포의 생성 방법
|
WO2020254355A1
(en)
|
2019-06-19 |
2020-12-24 |
F. Hoffmann-La Roche Ag |
Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
CN114080451B
(zh)
|
2019-06-19 |
2024-03-22 |
豪夫迈·罗氏有限公司 |
通过使用Cre mRNA进行的靶向整合来产生蛋白质表达细胞的方法
|
EP3986927A1
(en)
|
2019-06-19 |
2022-04-27 |
F. Hoffmann-La Roche AG |
Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
CN114026224B
(zh)
|
2019-06-26 |
2024-03-15 |
豪夫迈·罗氏有限公司 |
具有sirt-1基因敲除的哺乳动物细胞系
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
JP2022543551A
(ja)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Gprc5dに結合する抗体
|
CR20220019A
(es)
|
2019-07-31 |
2022-02-11 |
Hoffmann La Roche |
Anticuerpos que se fijan a gprc5d
|
AU2020327000A1
(en)
*
|
2019-08-08 |
2022-03-31 |
Regeneron Pharmaceuticals, Inc. |
Novel antigen binding molecule formats
|
PE20221906A1
(es)
|
2019-09-18 |
2022-12-23 |
Genentech Inc |
Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso
|
AU2020364071A1
(en)
|
2019-10-10 |
2022-05-26 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
WO2021094508A1
(en)
|
2019-11-15 |
2021-05-20 |
F. Hoffmann-La Roche Ag |
Prevention of visible particle formation in aqueous protein solutions
|
KR20220113791A
(ko)
|
2019-12-18 |
2022-08-16 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ccl2 항체
|
US20210230278A1
(en)
|
2019-12-18 |
2021-07-29 |
Hoffmann-La Roche Inc. |
Antibodies binding to HLA-A2/MAGE-A4
|
AU2020412609A1
(en)
|
2019-12-23 |
2022-06-16 |
Genentech, Inc. |
Apolipoprotein L1-specific antibodies and methods of use
|
JP2023508596A
(ja)
|
2020-01-02 |
2023-03-02 |
エフ. ホフマン-ラ ロシュ アーゲー |
脳内の治療用抗体の量を決定するための方法
|
TW202140511A
(zh)
|
2020-01-15 |
2021-11-01 |
瑞士商赫孚孟拉羅股份公司 |
減少來自重組蛋白生產過程中的雜質之方法
|
EP4127153A2
(en)
|
2020-03-26 |
2023-02-08 |
Genentech, Inc. |
Modified mammalian cells having reduced host cell proteins
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
EP4149421A1
(en)
|
2020-05-15 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Prevention of visible particle formation in parenteral protein solutions
|
CN115605185A
(zh)
|
2020-05-19 |
2023-01-13 |
豪夫迈·罗氏有限公司(Ch) |
螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途
|
AR122569A1
(es)
|
2020-06-08 |
2022-09-21 |
Hoffmann La Roche |
Anticuerpos anti-vhb y métodos de uso
|
BR112022025675A2
(pt)
|
2020-06-16 |
2023-03-07 |
Hoffmann La Roche |
Método para determinar antígeno livre
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
AU2021291011A1
(en)
|
2020-06-19 |
2023-01-05 |
F. Hoffmann-La Roche Ag |
Antibodies binding to CD3 and CD19
|
TW202216766A
(zh)
|
2020-06-19 |
2022-05-01 |
瑞士商赫孚孟拉羅股份公司 |
與cd3結合之抗體
|
WO2021255143A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and folr1
|
JP2023533217A
(ja)
|
2020-06-24 |
2023-08-02 |
ジェネンテック, インコーポレイテッド |
アポトーシス耐性細胞株
|
EP4175650A1
(en)
|
2020-07-06 |
2023-05-10 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
JP2023532764A
(ja)
|
2020-07-07 |
2023-07-31 |
エフ. ホフマン-ラ ロシュ アーゲー |
治療用タンパク質製剤の安定剤としての代替界面活性剤
|
PE20231300A1
(es)
|
2020-07-17 |
2023-08-24 |
Genentech Inc |
Anticuerpos anti-notch2 y metodos de uso
|
US11919958B2
(en)
|
2020-08-19 |
2024-03-05 |
Xencor, Inc. |
Anti-CD28 compositions
|
CA3192344A1
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
IL301258A
(en)
|
2020-09-21 |
2023-05-01 |
Genentech Inc |
Purification of multispecific antibodies
|
CA3195257A1
(en)
|
2020-09-24 |
2022-03-31 |
F. Hoffmann-La Roche Ag |
Mammalian cell lines with gene knockout
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
WO2022108627A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
EP4261225A1
(en)
|
2020-12-10 |
2023-10-18 |
Eutilex Co., Ltd. |
Anti-pd-1 antibody and uses thereof
|
JP7326584B2
(ja)
|
2020-12-17 |
2023-08-15 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗hla-g抗体及びその使用
|
EP4267734A1
(en)
|
2020-12-22 |
2023-11-01 |
F. Hoffmann-La Roche AG |
Oligonucleotides targeting xbp1
|
KR20230124959A
(ko)
|
2020-12-23 |
2023-08-28 |
이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 |
항-b7-h3 항체 및 이의 용도
|
WO2022146003A1
(ko)
*
|
2020-12-29 |
2022-07-07 |
삼성바이오로직스 주식회사 |
이중 또는 다중 특이적 항체
|
CN114716548A
(zh)
|
2021-01-05 |
2022-07-08 |
(株)爱恩德生物 |
抗-fgfr3抗体及其用途
|
US20240059789A1
(en)
|
2021-01-28 |
2024-02-22 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
WO2022169872A1
(en)
|
2021-02-03 |
2022-08-11 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
EP4295154A1
(en)
|
2021-02-18 |
2023-12-27 |
F. Hoffmann-La Roche AG |
Method for resolving complex, multistep antibody interactions
|
TWI830151B
(zh)
*
|
2021-02-19 |
2024-01-21 |
大陸商信達生物製藥(蘇州)有限公司 |
抗GPRC5DxBCMAxCD3三特異性抗體及其用途
|
WO2022192403A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
WO2022192647A1
(en)
|
2021-03-12 |
2022-09-15 |
Genentech, Inc. |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
JP2024513474A
(ja)
|
2021-04-09 |
2024-03-25 |
エフ. ホフマン-ラ ロシュ アーゲー |
異種ポリペプチドを発現する細胞クローンを選択するための方法
|
JP2024514222A
(ja)
|
2021-04-19 |
2024-03-28 |
ジェネンテック, インコーポレイテッド |
改変された哺乳動物細胞
|
WO2022246259A1
(en)
|
2021-05-21 |
2022-11-24 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
CN113278071B
(zh)
|
2021-05-27 |
2021-12-21 |
江苏荃信生物医药股份有限公司 |
抗人干扰素α受体1单克隆抗体及其应用
|
EP4355778A1
(en)
*
|
2021-06-17 |
2024-04-24 |
Boehringer Ingelheim International GmbH |
Novel tri-specific binding molecules
|
CA3221735A1
(en)
|
2021-06-18 |
2022-12-22 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ccl2 antibodies
|
WO2023287663A1
(en)
|
2021-07-13 |
2023-01-19 |
Genentech, Inc. |
Multi-variate model for predicting cytokine release syndrome
|
CN117642427A
(zh)
*
|
2021-07-14 |
2024-03-01 |
江苏恒瑞医药股份有限公司 |
特异性结合cd38、bcma和cd3的抗原结合分子及其医药用途
|
WO2023001884A1
(en)
|
2021-07-22 |
2023-01-26 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
CN113603775B
(zh)
|
2021-09-03 |
2022-05-20 |
江苏荃信生物医药股份有限公司 |
抗人白介素-33单克隆抗体及其应用
|
CN113683694B
(zh)
|
2021-09-03 |
2022-05-13 |
江苏荃信生物医药股份有限公司 |
一种抗人tslp单克隆抗体及其应用
|
WO2023094282A1
(en)
|
2021-11-25 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Quantification of low amounts of antibody sideproducts
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
WO2023117325A1
(en)
|
2021-12-21 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Method for the determination of hydrolytic activity
|
WO2023129974A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
TW202340251A
(zh)
|
2022-01-19 |
2023-10-16 |
美商建南德克公司 |
抗notch2抗體及結合物及其使用方法
|
WO2023175171A1
(en)
|
2022-03-18 |
2023-09-21 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Bk polyomavirus antibodies and uses thereof
|
WO2023202967A1
(en)
|
2022-04-19 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
WO2023232961A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024079015A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and imids
|
WO2024079009A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and proteasome inhibitors
|
WO2024079010A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and cd38 antibodies
|
WO2024079069A1
(en)
|
2022-10-12 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Method for classifying cells
|
CN117805397A
(zh)
*
|
2024-02-29 |
2024-04-02 |
军科正源(北京)药物研究有限责任公司 |
检测游离vegf的方法
|